(b).

Parameters	n = 511	eIF3E expression		p value	eIF3F expression		p value	eIF3G expression		p value	eIF3H expression		p value	eIF3I expression		p value
		High (n = 255)	Low (n = 256)		High (n = 253)	Low (n = 258)		High (n = 259)	Low (n = 252)		High (n = 257)	Low (n = 254)		High (n = 254)	Low (n = 257)
Age (years, mean ± SEM)	<65	103	116	0.3652	94	125	0.0367∗	112	107	0.7861	111	108	0.7856	110	109	0.7856
	≥65	140	133		144	129		136	137		134	139		133	140
	No data
Gender	Females	141	136	0.6574	148	129	0.0622	157	120	0.0034∗	134	143	0.3749	141	136	0.5945
	Males	114	120		105	129		102	132		123	111		113	121
Pathological stage	I/II	186	209	0.0297∗	189	206	0.1599	195	200	0.4484	186	209	0.0066∗	198	197	>0.9999
	III/IV	64	44		60	48		58	50		67	41		54	54
	No data
Residual tumour	R0	172	170	0.0456∗	178	164	0.6275	176	166	0.3280	178	164	0.2123	184	158	0.4592
	R1/R2	13	4		10	7		11	6		12	5		11	6
	RX/no data
Smoking history	1	35	40	0.7074	34	41	0.5315	44	31	0.1329	32	43	0.2107	42	33	0.2113
	2/3/4/5	209	213		210	212		206	216		215	207		202	220
	No data
Radiation therapy	No	190	206	0.3274	195	201	0.7789	200	196	0.8890	192	204	0.1616	191	205	0.8883
	Yes	32	26		27	31		30	28		34	24		29	29
	No data
Targeted molecular therapy	No	149	153	0.8417	153	149	0.3180	159	143	0.3181	148	154	0.7650	141	161	0.4841
	Yes	72	78		68	82		71	79		76	74		76	74
	No data
Mutations in KRAS/EGFR/ALK	No	78	54	0.1252	77	55	0.8913	64	68	0.2853	72	60	0.1723	81	51	0.4148
	Yes	66	29		57	38		53	42		61	34		53	42
	No data